MEK and the Inhibitors: From Bench to Bedside

Authors

Akintunde Akinleye, Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY 10595, USA. DELONG_LIU@NYMC.EDU.
Muhammad Furqan
Nikhil Mukhi
Pavan Ravella
Delong Liu

Author Type(s)

Faculty

DOI

10.1186/1756-8722-6-27

Journal Title

Journal of Hematology & Oncology

First Page

27

Document Type

Article

Publication Date

4-12-2013

Abstract

Four distinct MAP kinase signaling pathways involving 7 MEK enzymes have been identified. MEK1 and MEK2 are the prototype members of MEK family proteins. Several MEK inhibitors are in clinical trials. Trametinib is being evaluated by FDA for the treatment of metastatic melanoma with BRAF V600 mutation. Selumetinib has been studied in combination with docetaxel in phase II randomized trial in previously treated patients with advanced lung cancer. Selumetinib group had better response rate and progression-free survival. This review also summarized new MEK inhibitors in clinical development, including pimasertib, refametinib, PD-0325901, TAK733, MEK162 (ARRY 438162), RO5126766, WX-554, RO4987655 (CH4987655), GDC-0973 (XL518), and AZD8330.

Recommended Citation

Akinleye, A., Furqan, M., Mukhi, N., Ravella, P., & Liu, D. (2013). MEK and the Inhibitors: From Bench to Bedside. Journal of Hematology & Oncology, 6, 27. https://doi.org/10.1186/1756-8722-6-27